It is what?
The Abbott-created LibreLink app links to a continuous glucose monitor (CGM), which is a white disc that covers a needle that is usually put beneath the user’s skin in the arm or abdomen.
People with Type 1 diabetes use the CGM to continuously monitor their blood glucose levels, also known as blood sugar, so they don’t need to prick their fingertips to draw blood all the time to get readings.
People can choose whether to eat or exercise more wisely by continuously monitoring their glucose levels.
Additionally, and maybe more importantly, it can warn the user or their family members if their blood sugar level is too high or too low.
Abbott has faced criticism when its Libre 2 CGM for some Apple users’ LibreLink app stopped working.
The issue, according to Abbott, surfaced when the LibreLink app was upgraded to provide consumers with a substantial quality-of-life boost by eliminating the need to manually scan the disc with a smartphone.
The new upgrade would eliminate the requirement for a scan by enabling the CGM to provide data to the app continually. Dexcom, an adversary of Abbott, already permits this.
However, due to a bug in the update, some iPhone users have reported that the app has completely ceased working for them, making it impossible for them to monitor their blood sugar levels.
